Jade Biosciences, Inc. (JBIO) stock
JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$15.31+0.25 (+1.66%)
Close on Nov 20, 2026Market cap $973.68MP/E –Yield –
Jade Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Jade Biosciences's free cash flow for the twelve months ending Dec 31, 2025 was -$94.89M. For fiscal 2025 it was -$94.89M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$94.89M | – |
| FY2023 | Dec 31, 2023 | -$56.92M | – |
| FY2022 | Dec 31, 2022 | -$39.32M | – |
| FY2021 | Dec 31, 2021 | -$27.58M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$33.65M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.18M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.64M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.97M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.75M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.01M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.69M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.18M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.58M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.82M | – |
See a number that looks wrong?